Jubilant Ingrevia Limited (JUBLINGREA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Jubilant Ingrevia Limited ₹384, price ₹638, upside -39.8%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jubilant Ingrevia Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹349.26 – ₹850.29 · fair‑value band ₹202.70 – ₹484.57 · the ₹638.00 price screens above the ₹383.89 fair value. Dashed = 300-day average. As of Oct 1, 2026.
Follow Jubilant Ingrevia in your weekly email
Every Wednesday you see whether Jubilant Ingrevia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates.
Show more
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Stock analysis
Jubilant Ingrevia Limited (JUBLINGREA) currently trades at ₹638.00, while our model-based Fair Value estimate is ₹383.89, 39.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹592.88 per share, and 2 of the 26 models we run sit above the ₹638.00 price.
Bear case: the Dividend Discount group reads lowest at ₹64.26, and 24 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹202.70 (bear) to ₹484.57 (bull), the price of ₹638.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Jubilant Ingrevia Limited reported revenue of ₹43.9B in FY2026 versus ₹49.1B in FY2022, a compound −2.8%/yr. Reported net income was ₹2.8B in FY2026, compounding −12.6%/yr from FY2022.
Key figures
Market cap ₹101B (≈ $1.1B) · P/E ratio 32.8 · P/S ratio 2.08 · EPS (TTM) ₹19.47 · Dividend yield 0.8% · Net margin 6.3% · Return on equity 9.2% · Return on assets (EBIT) 10.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −46% fair-value upside, at −40%, JUBLINGREA screens cheaper than that median.
Fair Value models
Bear ₹202.70Fair Value ₹383.89Bull ₹484.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹7.37 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.2%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.5%
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.0%
Dividend (yield on the price)0.8%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 9%
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +34.6% a year for the price and +6.6% for the forecasts.
Compare Jubilant Ingrevia Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 696 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside−39.8% · Below median
Profitability
Return on equity (TTM)9.2% · Above median
Return on assets4.7% · Above median
Net margin (TTM)6.6% · Above median
Operating margin (TTM)11.4% · Above median
Growth and dividend
Revenue growth25.3% · Above median
Dividend yield (TTM)0.8% · Below median
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)32.8× · Pricier than median
P/B3.24× · Priciest 25%
P/S (TTM)2.18× · Pricier than median
P/FCF62.3× · Priciest 25%
EV/EBITDA16.5× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 54
PAST (return on equity)37· sector 26
HEALTH (low debt)95· sector 95
DIVIDEND (yield)16· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Jubilant Ingrevia Limited (JUBLINGREA) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹383.89 versus a price of ₹638.00, about −40% upside (overvalued).
What is the fair value of JUBLINGREA?
Our model-based fair value for Jubilant Ingrevia Limited is ₹383.89 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹638.00.
What is the quality score of JUBLINGREA?
Jubilant Ingrevia Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jubilant Ingrevia Limited (JUBLINGREA)?
Our model-based price target is the fair value of ₹383.89 (as of Oct 1, 2026) from 26 valuation models. Cautious scenario ₹202.70, optimistic scenario ₹484.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Jubilant Ingrevia Limited stock forecast for 2026?
Our models put fair value at ₹383.89, about −40% upside versus a price of ₹638.00 (overvalued). Cautious scenario ₹202.70, optimistic scenario ₹484.57. The calculation is refreshed regularly with new filings.
What is the revenue of Jubilant Ingrevia Limited (JUBLINGREA)?
Jubilant Ingrevia Limited reported trailing-twelve-month revenue of about ₹46.5B (latest available figure, as of Oct 1, 2026).
Does Jubilant Ingrevia Limited pay a dividend?
Jubilant Ingrevia Limited currently shows a dividend yield of about 0.78% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Jubilant Ingrevia Limited (JUBLINGREA)?
For today's price to be fair in a discounted-cash-flow model, Jubilant Ingrevia Limited would have to grow free cash flow by +40.1 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +45.2 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of JUBLINGREA use?
Our models discount Jubilant Ingrevia Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.27, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jubilant Ingrevia Limited that is +40.1 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Jubilant Ingrevia Limited (JUBLINGREA) delivered so far?
Over the past 5 years revenue at Jubilant Ingrevia Limited grew +45.2 % a year. The price currently implies +40.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jubilant Ingrevia Limited (JUBLINGREA) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Jubilant Ingrevia Limited (+40.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jubilant Ingrevia Limited (JUBLINGREA)?
The free-cash-flow yield on the price is 1.61 %: that much free cash flow Jubilant Ingrevia Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jubilant Ingrevia Limited (JUBLINGREA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jubilant Ingrevia Limited it is ₹383.89 per share (as of Oct 1, 2026), against a price of ₹638.00. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Jubilant Ingrevia Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, JUBLINGREA trades above its calculated fair value: price ₹638.00, fair value ₹383.89, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JUBLINGREA?
No. The price is what the market pays today (₹638.00); the fair value is what the company's own numbers justify (₹383.89). For Jubilant Ingrevia Limited the two are ₹254.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jubilant Ingrevia Limited worth?
The market values Jubilant Ingrevia Limited at about ₹101B (market capitalisation, as of Oct 1, 2026). Per share that is ₹638.00; our models calculate a fair value of ₹383.89 per share.
What do the bullish and bearish scenarios say about JUBLINGREA?
Our models span a range for Jubilant Ingrevia Limited: cautious scenario ₹202.70, base ₹383.89, optimistic ₹484.57 per share (as of Oct 1, 2026, price ₹638.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JUBLINGREA?
Jubilant Ingrevia Limited trades at a price-to-earnings ratio of 32.8 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹383.89 is built from several models across several years. Other multiples: P/B 3.2, P/S 2.2, EV/EBITDA 16.5.
How solid is the balance sheet of Jubilant Ingrevia Limited (JUBLINGREA)?
Balance-sheet figures for Jubilant Ingrevia Limited (as of Oct 1, 2026): return on equity 9.2%, debt of 0.10 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is JUBLINGREA from its 52-week high?
Jubilant Ingrevia Limited trades at ₹638.00, about 16% below its 52-week high of ₹763.80 and 18% above the low of ₹541.30 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹383.89 is for.
Which stocks are comparable to Jubilant Ingrevia Limited?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jubilant Ingrevia Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹638.00, calculated fair value ₹383.89 (−40%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JUBLINGREA calculated?
We run Jubilant Ingrevia Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹383.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Jubilant Ingrevia Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jubilant Ingrevia Limited (JUBLINGREA)?
The closing price on Oct 1, 2026 was ₹638.00. Our model-based fair value is ₹383.89, about −40% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jubilant Ingrevia Limited right now?
The price sits above even our optimistic bull case (₹484.57). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹202.70 to ₹484.57) leaves room in how you read the outcome.
Key figures of Jubilant Ingrevia Limited
How large is the market capitalisation of Jubilant Ingrevia Limited (JUBLINGREA)?
The market capitalisation of Jubilant Ingrevia Limited is ₹101B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jubilant Ingrevia Limited (JUBLINGREA)?
The price-to-sales ratio of Jubilant Ingrevia Limited is 2.08 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jubilant Ingrevia Limited (JUBLINGREA)?
Earnings per share at Jubilant Ingrevia Limited are ₹19.47 (price ÷ EPS = P/E 32.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jubilant Ingrevia Limited (JUBLINGREA)?
The dividend yield of Jubilant Ingrevia Limited is 0.8% (payout 25.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jubilant Ingrevia Limited (JUBLINGREA)?
The net margin of Jubilant Ingrevia Limited is 6.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jubilant Ingrevia Limited (JUBLINGREA)?
The return on equity (ROE) of Jubilant Ingrevia Limited is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jubilant Ingrevia Limited (JUBLINGREA)?
On an EBIT basis the return on assets of Jubilant Ingrevia Limited is 10.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jubilant Ingrevia Limited (JUBLINGREA)?
The operating margin of Jubilant Ingrevia Limited is 11.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jubilant Ingrevia Limited (JUBLINGREA)?
Revenue at Jubilant Ingrevia Limited is growing +25.3% versus a year earlier (3y avg −2.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jubilant Ingrevia Limited (JUBLINGREA)?
Earnings per share at Jubilant Ingrevia Limited are growing +40.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jubilant Ingrevia Limited (JUBLINGREA) carry?
The net debt of Jubilant Ingrevia Limited is ₹6.0B (fiscal year 2026, ≈ 3.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jubilant Ingrevia Limited in the live analysis
One click puts Jubilant Ingrevia Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
